Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q1 2024 net loss widens to $39.5 million; adjusted EPS falls to $0.96

Negative Impact 4 of 5 earnings Written later

ICU Medical reported first quarter 2024 revenue of $566.7 million, down slightly from $568.6 million a year earlier, and a GAAP net loss of $39.5 million, or $1.63 per diluted share, versus a $9.8 million loss, or $0.41 per share, in the first quarter of 2023. Adjusted diluted earnings per share fell to $0.96 from $1.74, and adjusted EBITDA fell to $78.8 million from $102.0 million, so headline profit measures declined for shareholders.

Key points

  • Q1 2024 revenue was $566.7 million versus $568.6 million in Q1 2023.
  • GAAP net loss was $39.5 million, or $1.63 per diluted share, versus a $9.8 million loss, or $0.41 per share, a year earlier.
  • Adjusted diluted EPS was $0.96 versus $1.74; adjusted EBITDA was $78.8 million versus $102.0 million.
  • The filing includes a fiscal year 2024 outlook showing a GAAP net loss of $127 million to $110 million and adjusted diluted EPS of $4.40 to $5.10.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECMay 7, 2024, 4:07 PM ET
Accession number0000883984-24-000014

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.